Clinical Scorecard: Assessment of Clinical Risk Factors and Survival Outcomes in Postoperative Recurrence or Metastasis of Colorectal Cancer

At a Glance

Key Highlights

• Colorectal cancer accounts for 10% of new cancers worldwide.
• 5-year survival rate drops to less than 5% after recurrence or metastasis.
• Local recurrence rate after radical surgery is 4% to 30%.
• MFI assessed via preoperative MRI is crucial for prognosis.
• Adjuvant therapy follows NCCN guidelines and includes XELOX or CAPOX regimens.

Guideline-Based Recommendations

Diagnosis

• Preoperative colonoscopy and imaging (CT/MRI) to assess metastasis.

Management

• Adjuvant chemotherapy regimens based on NCCN guidelines.

Monitoring & Follow-up

• Follow-up through inpatient/outpatient records and telephone follow-up.

Risks

• High risk of recurrence and metastasis post-surgery.

Patient & Prescribing Data

Patients with cT1-cT3 and cT4 colorectal malignant tumors without distant metastasis.

78.3% completed full 6-month adjuvant chemotherapy; early discontinuation due to adverse reactions was noted.

Clinical Best Practices

• Adhere to NCCN guidelines for diagnosis and treatment.
• Conduct thorough preoperative imaging to assess MFI.
• Ensure adequate lymph node retrieval during surgery.

References

• International Agency for Research on Cancer (IARC)
• National Comprehensive Cancer Network (NCCN) Guidelines
• Royal College of Radiologists (RCR) Guidelines
• Chinese Colorectal Cancer Diagnosis and Treatment Norms